These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Creation of lysine-deficient mutant lymphotoxin-alpha with receptor selectivity by using a phage display system. Yoshioka Y; Watanabe H; Morishige T; Yao X; Ikemizu S; Nagao C; Ahmad S; Mizuguchi K; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S Biomaterials; 2010 Mar; 31(7):1935-43. PubMed ID: 19853911 [TBL] [Abstract][Full Text] [Related]
6. Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2. Boschert V; Krippner-Heidenreich A; Branschädel M; Tepperink J; Aird A; Scheurich P Cell Signal; 2010 Jul; 22(7):1088-96. PubMed ID: 20206684 [TBL] [Abstract][Full Text] [Related]
7. Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology. Nomura T; Abe Y; Kamada H; Inoue M; Kawara T; Arita S; Furuya T; Minowa K; Yoshioka Y; Shibata H; Kayamuro H; Yamashita T; Nagano K; Yoshikawa T; Mukai Y; Nakagawa S; Tsunoda S; Tsutsumi Y Pharmazie; 2010 Feb; 65(2):93-6. PubMed ID: 20225650 [TBL] [Abstract][Full Text] [Related]
8. Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists. Mukai Y; Nakamura T; Yoshioka Y; Shibata H; Abe Y; Nomura T; Taniai M; Ohta T; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y J Biochem; 2009 Aug; 146(2):167-72. PubMed ID: 19386778 [TBL] [Abstract][Full Text] [Related]
9. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides. Qin W; Feng J; Li Y; Lin Z; Shen B Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837 [TBL] [Abstract][Full Text] [Related]
10. Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro. Schäfers M; Sommer C; Geis C; Hagenacker T; Vandenabeele P; Sorkin LS Neuroscience; 2008 Nov; 157(2):414-23. PubMed ID: 18838115 [TBL] [Abstract][Full Text] [Related]
11. A conformation-constrained peptide library based on insect defensin A. Zhao A; Xue Y; Zhang J; Gao B; Feng J; Mao C; Zheng L; Liu N; Wang F; Wang H Peptides; 2004 Apr; 25(4):629-35. PubMed ID: 15165719 [TBL] [Abstract][Full Text] [Related]
13. Collagen-induced arthritis in TNF receptor-1-deficient mice: TNF receptor-2 can modulate arthritis in the absence of TNF receptor-1. Tada Y; Ho A; Koarada S; Morito F; Ushiyama O; Suzuki N; Kikuchi Y; Ohta A; Mak TW; Nagasawa K Clin Immunol; 2001 Jun; 99(3):325-33. PubMed ID: 11358427 [TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Higuchi Y; McTiernan CF; Frye CB; McGowan BS; Chan TO; Feldman AM Circulation; 2004 Apr; 109(15):1892-7. PubMed ID: 15051641 [TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha and its receptors contribute to apoptosis of oligodendrocytes in the spinal cord of spinal hyperostotic mouse (twy/twy) sustaining chronic mechanical compression. Inukai T; Uchida K; Nakajima H; Yayama T; Kobayashi S; Mwaka ES; Guerrero AR; Baba H Spine (Phila Pa 1976); 2009 Dec; 34(26):2848-57. PubMed ID: 19949368 [TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of tumor necrosis factor receptors 1 and 2 of the goldfish (Carassius aurutus L.). Grayfer L; Belosevic M Mol Immunol; 2009 Jul; 46(11-12):2190-9. PubMed ID: 19446337 [TBL] [Abstract][Full Text] [Related]
17. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Shibata H; Yoshioka Y; Ikemizu S; Kobayashi K; Yamamoto Y; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Hayakawa T; Nagata S; Yamagata Y; Mayumi T; Kamada H; Tsutsumi Y Clin Cancer Res; 2004 Dec; 10(24):8293-300. PubMed ID: 15623605 [TBL] [Abstract][Full Text] [Related]
18. Mutants of lymphotoxin-α with augmented cytotoxic activity via TNFR1 for use in cancer therapy. Morishige T; Yoshioka Y; Narimatsu S; Ikemizu S; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S Cytokine; 2013 Feb; 61(2):578-84. PubMed ID: 23246116 [TBL] [Abstract][Full Text] [Related]
19. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. Kontermann RE; Münkel S; Neumeyer J; Müller D; Branschädel M; Scheurich P; Pfizenmaier K J Immunother; 2008 Apr; 31(3):225-34. PubMed ID: 18317365 [TBL] [Abstract][Full Text] [Related]
20. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Arnott CH; Scott KA; Moore RJ; Robinson SC; Thompson RG; Balkwill FR Oncogene; 2004 Mar; 23(10):1902-10. PubMed ID: 14661063 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]